These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 32073799

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
    Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M.
    J Natl Cancer Inst; 2012 Nov 21; 104(22):1712-23. PubMed ID: 23104323
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
    Navarro-Illana E, López-Lacort M, Navarro-Illana P, Vilata JJ, Diez-Domingo J.
    Vaccine; 2017 Jun 05; 35(25):3342-3346. PubMed ID: 28499554
    [Abstract] [Full Text] [Related]

  • 6. Nonavalent human papillomavirus vaccination as alternative treatment for genital warts.
    Bossart S, Gabutti MP, Seyed Jafari SM, Hunger RE.
    Dermatol Ther; 2020 Jul 05; 33(4):e13771. PubMed ID: 32500585
    [Abstract] [Full Text] [Related]

  • 7. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL, Joura EA.
    BioDrugs; 2011 Oct 01; 25(5):339-43. PubMed ID: 21942919
    [Abstract] [Full Text] [Related]

  • 8. HPV vaccines to prevent cervical cancer and genital warts: an update.
    Dochez C, Bogers JJ, Verhelst R, Rees H.
    Vaccine; 2014 Mar 20; 32(14):1595-601. PubMed ID: 24606637
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Population impact of HPV vaccines: summary of early evidence.
    Hariri S, Markowitz LE, Dunne EF, Unger ER.
    J Adolesc Health; 2013 Dec 20; 53(6):679-82. PubMed ID: 24263069
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The incidence of genital warts in Australian women prior to the national vaccination program.
    Brotherton JM, Heywood A, Heley S.
    Sex Health; 2009 Sep 20; 6(3):178-84. PubMed ID: 19653953
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.
    Petry KU, Bollaerts K, Bonanni P, Stanley M, Drury R, Joura E, Kjaer SK, Meijer CJLM, Riethmuller D, Soubeyrand B, Van Damme P, Bosch X.
    Hum Vaccin Immunother; 2018 Jul 03; 14(7):1800-1806. PubMed ID: 29553886
    [Abstract] [Full Text] [Related]

  • 18. Preventing cervical cancer and genital warts - How much protection is enough for HPV vaccines?
    Stanley M.
    J Infect; 2016 Jul 05; 72 Suppl():S23-8. PubMed ID: 27211079
    [Abstract] [Full Text] [Related]

  • 19. Human papillomavirus and genital cancer.
    Rapose A.
    Indian J Dermatol Venereol Leprol; 2009 Jul 05; 75(3):236-43; quiz 243-4. PubMed ID: 19439875
    [Abstract] [Full Text] [Related]

  • 20. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience.
    Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, Lindsay BR, Kuter BJ, Perez G, Dominiak-Felden G, Saah AJ, Drury R, Das R, Velicer C.
    Clin Infect Dis; 2016 Aug 15; 63(4):519-27. PubMed ID: 27230391
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.